|Description||HG6-64-1 is a potent and selective B-Raf and mutant B-Raf inhibitor; more information can be found in Patent WO 2011090738.|
|Synonyms||HG-6-64-1; HG 6-64-1|
BGB-283 is a selective Epidermal growth factor receptor and Proto oncogene protein b raf inhibitor under the development of BeiGene. BGB-283 shows antitumor act...
Vemurafenib is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity than...
Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.
ARQ 736 disodium salt
This active molecular is a Proto oncogene protein b raf and Vascular endothelial growth factor A inhibitor originated by ArQule. ARQ 736 is effective in killing...
BMS-908662 is a Raf kinase inhibitor with potential antineoplastic activity. It can specifically inhibit RAF kinases, located downstream from RAS in the RAS/RAF...
RAF265 is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30...
GDC-0879, a highly selective, potent, and orally bioavailable RAF small-molecule inhibitor. In GDC-0879-treated mice, both cell line- and patient-derived BRAF(...
MLN2480 is an oral, selective pan-Raf kinase inhibitor. The Raf kinases (A-Raf, B-Raf and C-Raf) are key regulators of cell proliferation and survival within th...
LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
CEP-32496, also known as AC013773, is an orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with...
SB-590885 is a selectively Raf kinases inhibitor, stabilizes the oncogenic B-Raf kinase domain in an active configuration, which is distinct from the previously...
B-Raf inhibitor 1
B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 μM and 2 nM for A375 proliferation and A375 p-ERK respectively.
PLX8394 is an orally bioavailable inhibitor of serine/threonine-protein kinase B-raf (BRAF) protein with potential antineoplastic activity. PLX8394 appears to s...
GW5074 is a c-Raf inhibitor. GW5074 has no direct effect on the activities of several apoptosis-associated kinases when assayed in vitro. In contrast to its eff...
This active molecular is a novel , paradox-breaking pan-RAF inhibitor with anti-SRC activity and it blocked growth of BRAF-mutant and NRAS-mutant melanoma cells...
PLX4720 is a 7-azaindole derivative that inhibits B-Raf(V600E) with an IC(50) of 13 nM, defines a class of kinase inhibitor with marked selectivity in both bioc...
AZ628 is a potent, ATP-competitive inhibitor of Raf kinases (IC50 values are 29, 34 and 105 nM for c-Raf1, B-RafV600E and wild-type B-Raf, respectively). It dis...
HG6-64-1 is a potent and selective B-Raf and mutant B-Raf inhibitor; more information can be found in Patent WO 2011090738.
AMG-628 is a highly selective, ATP-competitive inhibitor of Raf kinases. It can inhibit activation of tyrosine protein kinases. AMG-628 can also inhibit growth,...